Taking a Deep Dive Into Three-year Data on Lebrikizumab in AD With Raj Chovatiya, MD, PhD
Atopic dermatitis (AD) patients taking lebrikizumab (Ebglyss, Lilly) show a “sustained depth of response” for up to three years, according to new research presented at the 2025 American Academy of Dermatology’s annual meeting in Orlando, FL. Raj Chovatiya, MD, PhD, Founder and Director of the Center for Medical Dermatology and Immunology Research in Chicago, IL, discusses the topline […]